Calcineurin inhibitors: status quo and perspectives

Frank Erdmann, Matthias Weiwad
2011 Biomolecular Concepts  
AbstractDespite the fact that cyclosporin A (CsA) and tacrolimus (FK506) are very potent drugs in the treatment of serious autoimmune diseases and in the prevention of graft vs. host reactions or tissue rejections after allo- or xenotransplantations, modern transplantation medicine attempts to develop alternative medication regimes without these calcineurin inhibitors. The primary motivation for this endeavor is the high incidence of dramatic side effects upon immunosuppressive therapy. CsA and
more » ... ve therapy. CsA and FK506 target not only the calcineurin/NFAT pathway, but they also bind and inhibit members of distinct peptidyl-prolyl
doi:10.1515/bmc.2011.011 pmid:25962020 fatcat:yw4up7kg7vajnot7ekrndhhoke